Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289730 | 1.00 | MAPT (0.43) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL4750102 | 0.82 | MAPT (0.41) | MAPTHTTKMT2AMEN1GAA | |
| SCHEMBL4291328 | 0.82 | CA1 (0.38) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL4289461 | 0.82 | EBP (0.40) | MAPTKMT2AGAA | |
| SCHEMBL4294740 | 0.81 | MAN1B1 (0.43) | GAAPKM | |
| SCHEMBL4291053 | 0.80 | KDM4E (0.39) | MAPTSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4281787 | 0.80 | MEN1 (0.41) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL11909292 | 0.74 | HTT (0.49) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL11909294 | 0.74 | HTT (0.49) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4281693 | 0.74 | CCR3 (0.39) | RAB9ASMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAPT 3142/4885NPC1 1165/4885RAB9A 1247/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAPT 3142/4885NPC1 1165/4885RAB9A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.